T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of leukemia. Despite advances in treatments, 20 to 50 percent of patients relapse and have an extremely poor prognosis, highlighting the need to discover new targeted therapeutic approaches. Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, was recently awarded a 2021 AACR-Bayer Innovation and Discovery Grant (21-80-44-HERR) from the American Association for Cancer Research (AACR) in the amount of $50,000 to further explore a novel mitochondrial uncoupling drug in the treatment of leukemia and a potential therapeutic strategy against T-ALL. He shares more about the project. Read More